Drug Profile
Research programme: antibacterial agents - Taxis Pharmaceuticals
Alternative Names: TXA 497; TXY 436; TXY 541; TXY 9155Latest Information Update: 13 Jan 2020
Price :
$50
*
At a glance
- Originator TAXIS Pharmaceuticals
- Class Antibacterials
- Mechanism of Action Bacterial FtsZ protein inhibitors; Bacterial protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 13 Jan 2020 Preclinical development is ongoing in USA (Taxis Pharmaceutical website, January 2020)
- 13 Jan 2020 Research programme: antibacterial agents - Taxis Pharmaceuticals is available for licensing as of 13 Jan 2020. https://www.taxispharma.com/about/partnerships/ before January 2020 (Taxis Pharmaceutical website, January 2020)
- 13 Jan 2020 Taxis pharmaceutical has multiple patents pending for antimicrobial technology before January 2020